789 South Limestone Street
(859) 218-3859

Homepage Test


Maj-Linda Selenica, PhD

Dr. Selenica performed her graduate studies in Sweden where she studied the role of amyloid beta and tau proteins in Alzheimer Disease. Directly after her PHD, she received a postdoctoral fellowship at the University of South Florida, where she studied therapeutic approaches in tauopathy utilizing mouse models of AD/FTD.

Dr. Selenica joined College of Pharmacy at University of South Florida (2013) as a founding faculty member and basic scientist. As an independent PI, Dr. Selenica focuses in the pathological mechanisms behind TDP-43 and tauopathy in neurodegenerative disorders. In 2019 Selenica lab relocated to the University of Kentucky, Sanders-Brown Center (SBCoA), where they joined the Alzheimer’s disease Center (UK-ADC) and a collaborative group of neuroscientist and neurologist experts focused on Aging and dementia.

Research Focus

Our Laboratory research is focused on molecular pathways and therapeutic approaches of Alzheimer’s Disease, Frontotemporal Dementia (FTD) and related dementias. We have expanded beyond our knowledge on tauopathy and study the molecular mechanisms involved in TDP-43 proteinopathy in the multi-etiology of AD, LATE and FTD disease spectrum. Our laboratory has developed a comprehensive research program to study the impact of TDP-43 in neuropathology, neuroinflammation, blood brain barrier permeability and cellular stress. Specifically, we  study mechanistic pathways (hypusinated Eif5a) and post-translation modifications (acetylation, citrullination) that regulate tau and TDP-43 pathology in cellular and animal models. 

CCL2 Overexpression in the Brain Promotes Glial Activation and Accelerates Tau Pathology in a Mouse Model of Tauopathy Hypusination of Eif5a regulates cytoplasmic TDP-43 aggregation and accumulation in a stress-induced cellular modelTDP-43 mediated blood-brain barrier permeability and leukocyte infiltration promote neurodegeneration in a low-grade systemic inflammation mouse model

Our Methodology

The laboratory uttilizes cutting edge technology and novel assays to measure TDP-43 protein aggregation and accumulation